Arcturus Therapeutics (ARCT) has shared an update.
Meiji Holdings has announced the success of the Kostaive® bivalent mRNA COVID-19 vaccine in a Phase III clinical trial for booster vaccination in Japan. This comes after a distribution agreement with influenza vaccine leader Seqirus for the vaccine’s sales in Japan. Investors should note that this report contains forward-looking statements involving risks and uncertainties, and actual results may differ materially from those projected. The vaccine’s progress and commercial potential are subject to such risks, which are detailed in Arcturus Therapeutics Holdings Inc.’s regulatory filings.
Learn more about ARCT stock on TipRanks’ Stock Analysis page.
